What BMS doesn't sat in their press releases is always the real story:
1) that the action by NICE is limited to second-line use;
2) that they were forced to file a Patient Access Scheme reducing the price because they set the original price at an exorbitantly high level to take advantage of legislatively mandated patient access in the US;
3) that Roche also gained NICE approval for its BRAF inhibitor: and that they have been moving very slowly to gain FDA approval for their widely acclaimed version of anti-PD-1.

That being said, I am very happy to learn that metastatic melanoma patients in England and Wales will finally have access to these new drugs from BMS and Roche. Perhaps Scotland will be next? Perhaps Bristol Meyers-Squibb will speed up its efforts to bring anti-PD-1 to market and respond to the world-wide demand by melanoma patients, melanoma advocates and the entire oncology community.